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Background: Dysmenorrhea is a common menstrual complaint among adolescent girls and women of
reproductive age. The treatment of dysmenorrhea is typically selected from multidisciplinary options, including
complementary and alternative medicine such as acupuncture and moxibustion. However, there are few published
randomized controlled trials concerning moxibustion treatment for dysmenorrhea. This trial aims to investigate the
efficacy and safety of moxibustion for primary dysmenorrhea, and to identify the optimal time of moxibustion
treatment for primary dysmenorrhea.
Methods/Design: This protocol is for a randomized controlled trial in which the assessor and statistician will be
blinded. A total of 222 eligible patients with dysmenorrhea will be randomly assigned to three groups in a 1:1:1
ratio as treatment group A (treated before menstruation onset), treatment group B (treated at the onset of
menstruation), or control group C (waiting list group). The participants assigned to the treatment groups will
receive suspended moxibustion treatment at Sanyinjiao (SP6) and Guanyuan (CV4), while the waiting list group will
not receive moxibustion treatment until the completion of the study. The trial period will consist of three baseline
menstrual cycles, three menstrual cycles of treatment, and three menstrual cycles in the follow-up period. The
primary outcome will be measured by changes in the Cox Menstrual Symptom Scale and the secondary outcomes
will be measured using the Visual Analogue Scale, Cox Retrospective Symptom Scale, diary entries, the Self-rating
Depression Scale, and the Self-rating Anxiety Scale. The safety of moxibustion will be assessed at every visit.
Discussion: This trial aims to assess the effectiveness and safety of moxibustion for primary dysmenorrhea, as well
as to determine whether the optimal time of treatment for primary dysmenorrhea in clinical practice is before or
after the onset of menstrual pain.
Trial registration: Chinese Clinical Trial Register: ChiCTR-TRC-14004627, registered on 9 May 2014.
Keywords: Moxibustion, Primary dysmenorrhea, Intervention time, Efficacy, RCT, Study protocolBackground
Dysmenorrhea is a common menstrual complaint among
adolescent girls and women of reproductive age [1]. It
usually consists of two subcategories: primary and sec-
ondary dysmenorrhea. The focus of this paper is primary
dysmenorrhea (PD), which is defined as painful menses* Correspondence: wuxi403@126.com; acuresearch@126.com
†Equal contributors
1Chengdu University of Traditional Chinese Medicine, NO.37, Shierqiao Road,
Jinniu District, Chengdu, Sichuan 610072, China
Full list of author information is available at the end of the article
© 2015 Yang et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.in women with normal pelvic anatomy. Studies using
different measurements have reported the prevalence of
PD as between 20 and 90% of adolescent girls [2]. An
Australian study found the prevalence of dysmenorrhea
varied between 16 and 91%, with symptoms becoming
severely painful in 2 to 29% of the women studied [3].
Dysmenorrhea has a significant impact on women’s
lives and represents a substantial public health burden
[4-6]. Several studies have shown that female individuals
with dysmenorrhea report that it affects their academic
performance and social and sporting activities, which ishis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Yang et al. Trials  (2015) 16:35 Page 2 of 9a distressing finding given the availability of effective med-
ications [7,8]. Nonsteroidal anti-inflammatory drugs are
widely used as first-line therapy for women with dysmen-
orrhea [9,10]. However, in some women the side effects
may not be well tolerated or the pain relief provided may
be inadequate. Therefore, a large number of patients with
PD are turning to complementary and alternative medi-
cine such as acupuncture and moxibustion [11].
Moxibustion is widely used in Asian countries as a
part of Traditional Chinese Medicine (TCM). It is a
thermal treatment that involves placing ignited material
(usually Artemisia vulgaris) near acupuncture points to
cause a warm and painless sensation [12]. Moxibustion
is used to regulate the meridians and visceral organs of
the human body [13]. Suspended moxibustion is com-
monly used, which refers to the application of a burning
moxa stick over the acupuncture points from a distance.
In TCM, dysmenorrhea is etiologically caused by the
stagnated blood or Qi circulation in the uterus. The
pathological factors are mostly dampness, blood stasis,
and Qi obstructions. Moxibustion as a therapy features
on the effect of heat and Artemisia argyi, and thus can
improve blood circulation in the uterus and its sur-
rounding veins, and also help to absorb local patho-
logical discharges in patients with PD. It is considered
effective in resolving blood stagnation, Qi stagnation,
and discomposing cold-damp coagulation, leading to an
improved health state [14,15]. Clinical trials and system-
atic reviews have evaluated the effect of moxibustion for
conditions including dysmenorrhea [16], breech presen-
tation [17], ulcerative colitis [18], stroke [19], meno-
pausal hot flashes [20], and constipation [21].
Since ancient times, TCM has prescribed acupuncture
and moxibustion to treat dysmenorrhea. Acupuncture
stimulation, which involves thrusting or twisting needles,
results in various biochemical reactions that can have ef-
fects throughout the body; moxibustion uses heat stimula-
tion at various temperatures, from mild skin warmth to
tissue damage caused by burning. This heat stimulation
can yield inflammatory responses and induce vasodilation
by releasing mediators such as histamine and substance P
around the site of moxibustion therapy [22,23]. According
to TCM, the treatment of PD in clinical practice is usually
started before menstruation. Several studies have used dif-
ferent time sequences of acupressure in dysmenorrhea to
seek evidence-based medical proof regarding the appro-
priate point selection and timing of intervention in PD
[24]. Unfortunately, clinical trials regarding the optimal
time of moxibustion treatment intervention are lacking.
This is a protocol for a randomized controlled trial
(RCT) that aims to assess the efficacy and safety of
moxibustion, and to determine whether the optimal time
of treatment for PD is preventively or after menstrual
pain begins.Methods/Design
Setting
This RCT will be conducted in a single center, with the
assessor and statistician blinded to treatment allocation.
A total of 222 patients diagnosed with PD in accordance
with the Clinical Guidelines of Primary Dysmenorrhea
by the Society of Obstetricians and Gynecologists of
Canada will be enrolled in this trial [25]. The whole
treatment process will be carried out in the Third
Teaching Hospital of Chengdu University of Traditional
Chinese Medicine, Chengdu, Sichuan, China.
Patients
Recruitment strategies
There will be three strategies for PD patient recruitment.
First, participants will be recruited from the outpatient and
inpatient department of the Third Teaching Hospital of
Chengdu University of TCM. Second, printed recruitment
posters will be distributed in public clinics and nearby com-
munities. Third, advertisements will be published in the
campuses of Chengdu University of TCM, Sichuan Univer-
sity, Southwest University of Nationalities and Southwest
Universities of Finance and Economics, and Sichuan Voca-
tional and Technical College of Communications.
Inclusion criteria
Participants meeting the following criteria will be
included:
1. Aged from 18 to 30 years without history of
delivery,
2. Normal menstrual cycle (28 ± seven days) during the
last three months,
3. Diagnosed with PD according to the Primary
Dysmenorrhea Consensus Guidelines [25],
4. Diagnosed with the TCM pattern of stagnation of Qi
and blood, or retention of cold-damp coagulation
(see Table 1) [26],
5. Menstrual pain score of over 40 mm on the Visual
Analogue Scale (VAS),
6. Agree to keep a dysmenorrhea diary during the
study period, and
7. Agree with all procedures in this trial by signing a
written informed consent form.
Exclusion criteria
Participants meeting one or more of the following
criteria will be excluded:
1. Secondary dysmenorrhea caused by endometriosis,
uterine myoma, endometrial polyps, pelvic
inflammatory disease, or other gynecological
problems confirmed by a gynecological abdominal
ultrasound B examination;
Table 1 Traditional Chinese medicine pattern differentiation protocol for women with primary dysmenorrhea
Diagnostic patterns Items
Diagnostic pattern 1
Stagnation of Qi and blood Pain: distended, stabbing abdominal pain before or during the period aggravated by pressure.
Menstruation: dark purplish in color, clotty and hesitant or scanty in flow, pain relieved after clots discharged.
Accompanying symptoms: distending in breasts, mood swings.
Tongue: purplish.
Pulse: wiry.
Diagnostic pattern 2 Pain: distended, stabbing abdominal pain before or during the period, favorably to warmth, lower back pain.
Retention of cold-damp coagulation Menstruation: dark purplish in color, clotty and hesitant in flow, pain relieved after clots discharged.
Accompanying symptoms: distending in breasts, mood swings, and aversion to cold.
Tongue: pale and white greasy tongue coating.
Pulse: deep and slow.
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threatening condition or progressive central nervous
disorder);
3. Any other condition that the investigator judges as
likely to make the patient unable to complete,
comply, or unsuitable for the study;
4. Uncontrolled diagnosed psychiatric disorders;
5. Intent to have a baby during any period of the trial;
6. Having taken antidepressants, anti-serotonin,
barbiturates, or psychotropic drugs in the previous
two weeks; or
7. Currently receiving or having received any other
treatment for PD in the previous three months.
Sample size
A previous study found that the mean on the Cox Men-
strual Symptom Scale (CMSS) of PD patients after moxi-
bustion was 1.62 [24]. The average CMSS values of
subjects in the proposed study, with the square of stand-
ard deviation, are expected to be 1.7, 1.9, and 2.5 for pa-
tients treated with moxibustion before menstruation,
those treated at the time of menstrual onset, and the
waiting list group, respectively. In this case, the three
groups are set with the ratio of 1:1:1 as the statistical
power is 0.90 and the significance level is 0.05. The sam-
ple size was estimated by One Way ANOVA Power
Analysis (11th edition, NCSS, LLC, Utah, United States)
in NCSS-PASS (11th edition, NCSS, LLC, Utah, United
States). After the estimation, the effect size is 0.2266
with 64 patients in each group and 192 patients in total.
Therefore, there should ideally be 222 patients in total,
with each group containing no less than 74 patients, es-
timating a dropout rate is 15%.
Ethics
This study protocol was reviewed and approved by the
Institutional Review Board of the Teaching Hospital of
Chengdu University of Traditional Chinese Medicine inFebruary 2014 (approval number: 2013KL-034). The
present study was financially supported by the National
Natural Science Foundation of China and the trial was
registered in Chinese Clinical Trials Registry with the
identifier number ChiCTR-TRC-14004627. Prior to
undertaking any study-related procedures, all partici-
pants will provide written informed consent.Procedure
An independent assessor will initially assess each poten-
tial participant according to the inclusion and exclusion
criteria. After completing a screening test, participants
will enter a baseline period of three months (three men-
strual cycles) without moxibustion treatment, during
which they will be asked to record menstrual pain and
use of acute medication in a dysmenorrhea diary.Randomization
After participants have completed a baseline evaluation,
eligible subjects will be randomly classified into three
groups: treatment group A (treated before menstru-
ation), treatment group B (treated as the onset of men-
struation), and control group C (waiting list group). A
computer-generated, blocked random allocation se-
quence will be generated with SAS software (Version
9.1, SAS Institute Inc., NC, United States). Another re-
search coordinator who is not involved with data collec-
tion will provide the random number and group
assignment immediately to the independent assessor in
opaque, sealed envelopes. This procedure guarantees
that randomization concealment is adequate, and not in-
fluenced by the acupuncturists or participants. Random
allocation will be performed after the first visit to partic-
ipants who provide informed consent and meet the in-
clusion criteria. If a participant is eligible to be included
in the study, the researcher will open the corresponding
envelope in front of the participant. The envelopes will
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pleted all baseline assessments.
Figure 1 summarizes the design of the study and
Table 2 outlines the measures used in the trial. The dur-
ation of the study for every participant will be nine men-
strual cycles, including three menstrual cycles in the
baseline, treatment, and follow-up periods, respectively.
Blinding
Double blinding of the clinician and patient is unfeasible
owing to the unique nature of moxibustion operations.
However, to ensure the integrity of the trial, the re-
searchers will not assess the efficacy of treatment to
avoid misleading the patients and inducing potential im-
pacts on the compliance and outcome measurements.
The therapist, the assessors of therapeutic effect, the
data manager, and the statistician will be separated.
Moreover, according to the principle of blinding, only
patients allocated to the waiting list group will be told to
wait for free treatments at the end of the study; alloca-
tion information will be strictly withheld from patients
in the other two groups.
Interventions
Acupuncturists must receive a license from the Ministry
of Health of the People’s Republic of China and take an
educational course to ensure their strict adherence toFigure 1 Flow chart of the trial. Participants with a diagnosis of primary
Chengdu University of Traditional Chinese Medicine. All participants should
participants will be excluded. A total of 222 participants will be randomized to
treatment group B (treated at the onset of menstruation), or control group C
baseline menstrual cycles, three menstrual cycles of treatment, and three men
at every visit.and familiarity with the study before they become eli-
gible to treat patients in this study. Those participants
allocated to a treatment group will be requested to at-
tend (with their partner or support person if available) a
training course and demonstration session by their tu-
tors. The training course involves advice, demonstration
of moxibustion, and instructions on how to do moxibus-
tion safely at home. The woman or her partner or sup-
port person will be trained to light the moxibustion
sticks and to hold an individual stick 2.5 to 3 cm above
the two acupoints (SP6 and CV4). The participants will
be told not to make the acupoints uncomfortable during
treatment. They will be requested to perform this treat-
ment for five to 10 minutes on each acupoint once a day
for five to seven consecutive days, and will be supplied
with sufficient moxibustion sticks to do so in each treat-
ment period.
Rationale for selection of acupoints
The moxibustion treatment protocol to be used is con-
sistent with the principles of traditional moxibustion
theories. These principles state that the most common
causes of dysmenorrhea in TCM are blood stagnation
and cold-damp coagulation in the uterus. According to
previous surveys and expert consultations, Sanyinjiao
(SP6) and Guanyuan (CV4) are the most common acu-
points used in PD treatment. SP6 is the convergentdysmenorrhea will be recruited at the Third Teaching Hospital of
endure a baseline period of three menstrual cycles and inappropriate
three groups: treatment group A (treated before the menstruation),
(waiting list group) in a 1:1:1 ratio. The trial period will consist of three
strual cycles in the follow-up period, and the outcome will be measured
Table 2 Study design schedule
Period Baseline Inclusion Treatment Follow-up
Visit 1 2 3 4 5 6 7
Menstrual cycle −3 month 0 month 1 month 2 month 3 month 4 month 5 month 6 month
Patients √
Inclusion and exclusion criteria √
Informed consent √
Physical examination √ √
Medical history √
Comorbidities √ √ √ √ √ √ √
Outcomes
CMSS √ √ √ √ √ √
VAS √ √ √ √ √ √ √ √
RSS √
SDS and SAS √ √
Dysmenorrhea diary √ √ √ √ √ √ √ √
PGF2a, PGE2 √ √
Gynecological abdominal ultrasound B √
Trial evaluation
Patient’s compliance √ √
Reasons for dropout or withdrawals √ √
Adverse events √
Safety evaluation √
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ing to TCM, and is closely related to the lower abdomen
and uterus [27]. This makes SP6 one of the most com-
monly used points for gynecologic indications in clinical
practice, especially for alleviating dysmenorrhea. The
CV4 point in the conception vessel meridian is known
as the root of vital Qi, and can exert a regulatory effect
on the uterus because of its role of providing power to
vital movement. Moxibustion at CV4 can treat dysmen-
orrhea because of its function of warming the concep-
tion vessel meridian, tonifying vital Qi, and promoting
blood circulation to remove blood stasis.
Treatment group A (treated before menstruation)
Group A will be treated five days before expected men-
strual onset and treatment will continue until menstru-
ation begins. However, the subjects’ menstrual cycles
may change and so the actual period of treatment will
be five to seven days. The treatment will be the applica-
tion of a moxa stick (herbal preparation with Artemisia
vulgaris, Z32021062, Oriental Moxa Co., Suzhou, China)
at acupoints SP6 and CV4 to patients in a supine pos-
ition. The moxa roll is prepared by wrapping mugwort
wool (herbal medicines may be mixed in it) with a piece
of a paper. It is cylindrical, 1.5 cm in diameter, and
20 cm in length. A lighted moxa roll will be held 2.5to 3 cm above the acupoint and moved upwards and
downwards, to the left and right, or around. The pa-
tient should feel warmth but not scorching heat. Each
point will be treated with moxibustion for five to
10 minutes.
Treatment group B (treated within menstrual period)
Group B treatment will start as soon as menstruation
onsets, continuing for five consecutive days. The selec-
tion of acupoints and the procedure will be exactly the
same as described above for treatment group A.
Control group C (waiting list group)
Participants in this group will receive no moxibustion-
related intervention while the trial is in process. The
subjects in this group will be asked to maintain their
normal lifestyle, including diet, exercise, and workload.
At the end of the trial, if participants in group C would
like to be treated with moxibustion, we will offer free
moxibustion treatment five times monthly for three
menstrual cycles.
Outcome assessments
Primary outcome measurement
Cox Menstrual Symptom Scale (CMSS) The CMSS
has been widely used for integrally evaluating patients’
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toms. In the severity evaluation, each symptom is scored
via five levels: a score of 0 denotes that the symptom is
not noticeable; one denotes it as slightly bothersome;
two denotes it as moderately bothersome; three denotes
it as severely bothersome; and four denotes it as very se-
verely bothersome. In the duration evaluation, each
symptom is scored in five grades: a score of 0 denotes
that the symptom did not occur; one denotes that it
lasted less than three hours; two denotes that it lasted
between three and seven hours; three denotes that it
lasted an entire day; and four denotes that it lasted sev-
eral days. The CMSS will be used in each of the three
menstrual cycles of treatment and the three menstrual
cycles during the follow-up period.Secondary outcome measurements
Visual Analogue Scale The severity of menstrual pain
will be measured with the VAS, a 100-mm horizontal
line with endpoints from no pain on the far left to the
worst possible pain on the far right. The VAS is
scored by measuring in millimeters the distance from
the side marked no pain to the edge of the mark made
by the patient. Possible scores range from a minimum
of 0 to a maximum of 100 mm, as participants will
be asked to indicate a perception of pain intensity
scored from one to 100. The VAS will be used during
baseline measurements and during the first, second,
third, fourth, fifth, and sixth menstrual cycle after
inclusion.Cox Retrospective Symptom Scale The Cox Retro-
spective Symptom Scale (RSS) is a measurement of men-
strual symptoms that has been shown to have high
reliability, validity, and sensitivity [29]. It gives two
scores: a Total Frequency Ratings score (RSS COX1)
and an Average Severity Ratings score (RSS COX2).
Lower scores indicate better health. The RSS will be
used before treatment to assess the baseline condition of
the patient.Dysmenorrhea diary The women will be provided with
dysmenorrhea diaries to record the specific time of men-
strual pain attacks, the duration of dysmenorrhea, the
associated phenomena, and any medication used. This
information will be recorded daily during every men-
strual cycle of the three study periods. All patients will
be carefully instructed on how to use this diary to rate
their symptoms. The dysmenorrhea diary will be used
during baseline measurements and during the first, sec-
ond, third, fourth, fifth, and sixth menstrual cycle after
inclusion.Self-rating Depression Scale The Self-rating Depres-
sion Scale (SDS) is a 20-item self-reporting question-
naire on the symptoms of depression. Subjects rate each
item according to how they felt during the preceding
seven days. Item responses are ranked from one to four.
The sum of the 20 items produces a score between 20
and 80, with a score of greater than 40 suggesting clinic-
ally relevant depression [30]. The SDS will be used on
the day when menstruation ends in the last month of
the baseline period, and in the fourth menstrual cycle
after inclusion (after completion of three sessions of
treatment).
Self-rating Anxiety Scale The Self-rating Anxiety Scale
(SAS) has been widely used in research and in clinical
practice for the detection of anxiety [31]. It also consists
of 20 items rated on numerical values of one to four.
The total SAS score may vary from 20 (no anxiety at all)
to 80 (severe anxiety), with a value of greater than 40
suggesting the presence of a clinically relevant anxiety
disorder. The SAS will be used on the day when men-
struation ends in the last month of the baseline period,
and in the fourth menstrual cycle after inclusion (after
completion of three treatment sessions).
Follow-up
The follow-up assessment is designed to evaluate the
long-term effects of moxibustion. Upon completion of
treatment, follow-up assessments will be conducted at
the fourth, fifth, and sixth menstrual cycle after inclu-
sion, lasting three menstrual cycles. In addition, patients
will keep the daily dysmenorrhea diary and complete the
CMSS and VAS measurements during every menstrual
cycle in the follow-up period. Patients will send the rele-
vant information to researchers immediately via email or
short message service. To encourage participant compli-
ance, we will show special solicitude for every partici-
pant and closely monitor the evolution of their illness.
Statistical analysis plan
Data integrity
No record can be missed or omitted in the original data
source. Any corrections should be explained in the
appended notes signed and dated by the physicians par-
ticipating in the clinical trial; primary entries are not
allowed to be changed. After the observation of a clinical
case, case report form (CRF) files will be submitted to
the project directors for verification and signing by
supervisors.
Data input will be done separately by two data collec-
tors with computers and locked once the checking work
is done. The data manager will clarify any questions re-
garding the CRF with the researchers through clinical
supervisors. Researchers should answer any questions as
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the modification, validation, and entry of the data.
Analysis
A statistician blinded to the whole trial process will per-
form the statistical analysis using the SAS statistical soft-
ware package (Version 9.1, SAS Institute Inc.) in the
Computer Integrated Manufacturing System. For the
evaluation of curative effect in this trial, the per protocol
set (PPS) will be used. The full analysis set (FAS) is de-
termined according to an intention-to-treat population;
all patients who are randomized and receive at least one
treatment session will be included in the analysis set.
The PPS is defined as the patients who complete the
study and do not have major protocol violations. Demo-
graphic data and other basic indicators will be analyzed
to test the balance of the three groups at baseline. The
main indicators and global indicators will be analyzed
within the FAS and PPS. The results will be described
with the mean, standard deviation, median, P25 (Per-
centile 25), P75 (Percentile75), maximum, and minimum
values of the differences between the treatment period
and the baseline period. Between-group differences will
be tested using repeated measure analyses of variance.
The accepted level of significance for all analyses was
P <0.05. Considering that the efficacy might be affected
by factors such as age, age of menarche, and course of
disease, all factors will be considered as co-variants for
covariance analysis or logistic regression analysis when
comparisons among groups are made. Missing data will
be replaced according to the principle of multiple
imputations.
Safety monitoring
Possible adverse events (AEs) due to moxibustion in-
clude blisters, redness, itching, burns, and respiratory
symptoms. All unexpected and unintended responses
will be reported as AEs by the researcher at every visit,
even if they are not necessarily related to moxibustion
intervention. The AEs will be carefully recorded in the
CRF by the corresponding research staff.
Discussion
This proposed trial is a randomized, controlled clinical
trial with separation of the practitioner, assessor, and
statistician. The aims of this trial are to evaluate the effi-
cacy and safety of moxibustion for treating PD, and to
identify the optimal interventional time of moxibustion
for PD treatment.
The form of moxibustion used in this trial will be sus-
pended moxibustion treatment. When suspended moxi-
bustion is applied to acupoints, the patient will have
non-local or non-superficial heat sensation, such as
penetrating heat, expanding heat, and transmitting heat,as DeQi appears. Selection of optimal acupoints for PD
plays an important role in moxibustion treatment effect-
iveness. In practice, the treatment effect of moxibustion
is affected by many other influential factors, including
the intensity of heat stimulation, the ingredients of the
moxa pillar, and the moxibustion sensations experienced.
The most important factor contributing to the effective-
ness of moxibustion is thought to be the selection of
proper interventional time. However, in existing studies,
interventional timing of moxibustion was not included
as a key variant to be assessed.
In another undergoing study, we mainly focused on
the effectiveness of moxibustion for pain relief in PD,
which can be referred to the published protocol [32]. As
to the current one, it is conceived on the basis of the
former one. As indicated by the results from the initial
analysis, moxibustion is effective for PD pain manage-
ment; thus we want to further assess the impact of inter-
vention time of moxibustion on the outcome of treating
PD, so as the physiological tests’ change by treatment. In
clinical practice, moxibustion treatment for PD can also
be differed by the intervention timing in China, and
there is no relative study on this focus. Thus we carried
out the present study as a continuum which is reported
by the current protocol. It is anticipated that the result
may demonstrate the optimal interventional timing for
PD and further extend our understanding of interven-
tion from a chrono-therapeutic perspective, which will
be highlights of our further reports. Moreover, the
present study that was designed in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
statement, and guidelines will provide useful information
to guide the clinical practice of moxibustion for PD.
In addition, our study may also have the following
strengths which will be potential points of discussion in
the final reports. The dysmenorrhea diaries will be used
to record the symptoms and management of menstrual
pain in every menstrual cycle; these diaries are import-
ant for quality monitoring of the recurrence of new PD
episodes. Besides the evident physical concerns, PD may
be particularly disruptive to adolescent girls and women
who experience mood fluctuations, such as depression
or anxiety. There is increasing evidence that psycho-
logical disorders coexist with dysmenorrhea, and these
conditions may synchronize with menstrual pain. The
question remains whether anxiety and depression make
women prone to suffering from dysmenorrhea, or
whether dysmenorrhea causes anxiety and depression.
We believe that women with mood changes tend to have
lowered pain thresholds compared with mentally healthy
women. Anxiety and depression disrupt patients’ experi-
ences, expressions, behaviors, and pain-coping re-
sponses. Therefore, a better understanding of the
relationship between psychological characteristics and
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moxibustion as a treatment for PD. Hence, we will apply
the SAS and the SDS to examine the link between PD
and psychological symptoms of depression and anxiety
among dysmenorrhea sufferers.
On the other hand, there are also limitations to this
study. Concealment is the most critical factor in the allo-
cation process, with a high risk of bias possibly gener-
ated by unconcealed allocation [33]. One limitation of
this study is the possibility of a high risk of bias regard-
ing blinding, as the waiting list group will be used as a
control instead of a group receiving a sham procedure.
Another limitation is that as moxibustion treatment will
begin five to seven days before menstruation or at the
onset of pain, the treatment may interfere with the men-
strual period; treatment may cause menstruation to
occur one or two days sooner or later than the usual
cycle. Therefore, it may be difficult to predict an exact
menstruation start date for the patients, and this may
affect the therapeutic effect.
It is believed that this trial will provide good evidence
to demonstrate the efficacy and safety of moxibustion
for patients with PD. Moreover, it will be of great signifi-
cance for clinical practice to identify an optimal moxi-
bustion treatment time for PD.
Trial status
The trial is currently in the recruitment phase. Partici-
pant recruitment started in June 2014, and is expected
to end in September 2015.
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